BeOne Medicines Ltd.SSE: 688235

Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)

Jul 1, 2026 · Issued by BeOne Medicines Ltd. via Shanghai Stock Exchange

Filed with SSE · Jul 1, 2026 · 4 pages · Chinese

On 6ix: 6ix.com/news/beone-medicines-ltdvoluntary-announcement-on-progress-of-clinical-trial-of-brukinsa-zanubrutinib-capsules

Release

Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

BeOne Medicines Ltd. on 6ix

Earlier from BeOne Medicines

Announcement on the Handling of Relevant Tax MattersJun 27
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% ScaleJun 2
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell LymphomaMay 13
Report for Q1 2026May 12
BeOne Medicines Announces First Quarter 2026 Financial Results and Business UpdatesMay 6

Later from BeOne Medicines

Grant of Restricted Share UnitsJul 9
Announcement on Voluntary Disclosure of Holding Conference Call for Company PerformanceJul 18
Announcement on Voluntary Disclosure of Adjustment of Operating Performance Forecast for 2026Aug 6
Announcement on Convening the 2026 Semi-annual Performance BriefingAug 21
Semi-annual Report for 2026Aug 27

All BeOne Medicines news releases

Follow BeOne Medicines into a list and get an email when it puts out news.

Follow BeOne Medicines